Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease
✍ Scribed by L.S. Lamb Jr; S.A. Abhyankar; L. Hazlett; W. O'Neal; R.S. Folk; S. Vogt; R.S. Parrish; K. Bridges; P.J. Henslee-Downey; Adrian P. Gee
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 225 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0196-4763
No coin nor oath required. For personal study only.
✦ Synopsis
CD134 (OX-40
) is an activation-associated antigen which functions as a costimulatory receptor for CD4؉ T cells. In order to determine the expression of CD134 during immune recovery following allogeneic bone marrow transplantation (BMT), we measured its expression on T cells and T cell subsets during the first 100 days following BMT in 26 patients. CD4؉CD134؉ T could be seen approximately 14 days following BMT cells in patients who did not develop GvHD which required therapy (n ؍ 20). The percentage of CD4؉CD134؉ cells continued to increase up to the fourth week following BMT to a maximum of 40-50% of CD4؉ T cells (normal ؍ 1-8%). Two patients who developed Grade I-II GvHD and who responded to treatment with pulsed high-dose methylprednisolone (MPD) showed a decline of approximately 40% in CD4؉CD134؉ T cells was seen within 48 hours of treatment. Four patients who developed GvHD that was not responsive to MPD and who later developed high IV GvHD showed increasing CD4؉CD134؉ T cells up to 85% of the CD4؉ T cells. Additionally, rapid increases in CD134؉ T cells following antibody-based T cell therapy were associated with GvHD recurrence. In no cases was the percentage of CD134؉ CD4؉ T cells predictive of clinical GvHD. In this exploratory study, we have shown that CD134, although not predictive of the initial onset of GvHD, may be a useful tool for monitoring the response to early GvHD therapy and identification of patients at risk for reemergence of GvHD who may benefit from anti-T cell therapy. Cytometry (Comm. Clin. Cytometry